Bristol Myers Correlations

BMY Stock  USD 48.98  0.96  2.00%   
The current 90-days correlation between Bristol Myers Squibb and Inhibrx Biosciences, is 0.28 (i.e., Modest diversification). The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.

Bristol Myers Correlation With Market

Very weak diversification

The correlation between Bristol Myers Squibb and DJI is 0.49 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and DJI in the same portfolio, assuming nothing else is changed.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Moving against Bristol Stock

  0.54NTNX NutanixPairCorr
  0.39AXP American ExpressPairCorr
  0.38MMM 3M CompanyPairCorr
  0.36KMDA KamadaPairCorr
  0.36JPM JPMorgan ChasePairCorr
  0.34CSCO Cisco Systems Sell-off TrendPairCorr
  0.33MSFT Microsoft Earnings Call This WeekPairCorr
  0.31GE GE AerospacePairCorr
  0.31IBM International Business Earnings Call TodayPairCorr

Related Correlations Analysis

Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Risk-Adjusted Indicators

There is a big difference between Bristol Stock performing well and Bristol Myers Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Bristol Myers' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.